Tobin Schilke, the Chief Financial Officer of $CRNX, sold 6,713 shares of the company on 03-03-2026 for an estimated $266,304. We received data on the trade from a recent SEC filing. This was a sale of approximately 7.9% of their shares of this class of stock. Following this trade, they now own 78,121 shares of this class of $CRNX stock.
$CRNX Insider Trading Activity
$CRNX insiders have traded $CRNX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $CRNX stock by insiders over the last 6 months:
- MATTHEW K FUST sold 16,000 shares for an estimated $716,000
- DANA PIZZUTI (Chief Med and Dev Officer) has made 0 purchases and 4 sales selling 15,000 shares for an estimated $647,462.
- TOBIN SCHILKE (Chief Financial Officer) sold 6,713 shares for an estimated $266,304
- RICHARD SCOTT STRUTHERS (President & CEO) sold 4,000 shares for an estimated $180,000
- ISABEL KALOFONOS (Chief Commercial Officer) sold 2,500 shares for an estimated $137,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRNX Hedge Fund Activity
We have seen 137 institutional investors add shares of $CRNX stock to their portfolio, and 135 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAKER BROS. ADVISORS LP added 1,368,869 shares (+488.9%) to their portfolio in Q4 2025, for an estimated $63,720,851
- FARALLON CAPITAL MANAGEMENT LLC added 1,163,000 shares (+20.2%) to their portfolio in Q4 2025, for an estimated $54,137,650
- RTW INVESTMENTS, LP added 884,326 shares (+189.4%) to their portfolio in Q4 2025, for an estimated $41,165,375
- JENNISON ASSOCIATES LLC removed 763,133 shares (-37.3%) from their portfolio in Q4 2025, for an estimated $35,523,841
- VESTAL POINT CAPITAL, LP removed 750,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $34,912,500
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 644,918 shares (-74.1%) from their portfolio in Q4 2025, for an estimated $30,020,932
- CITADEL ADVISORS LLC removed 629,787 shares (-71.2%) from their portfolio in Q4 2025, for an estimated $29,316,584
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRNX Analyst Ratings
Wall Street analysts have issued reports on $CRNX in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 01/08/2026
- Morgan Stanley issued a "Overweight" rating on 01/06/2026
- Oppenheimer issued a "Outperform" rating on 09/30/2025
- Leerink Partners issued a "Outperform" rating on 09/29/2025
- JMP Securities issued a "Market Outperform" rating on 09/26/2025
- Baird issued a "Outperform" rating on 09/26/2025
- JP Morgan issued a "Overweight" rating on 09/24/2025
To track analyst ratings and price targets for $CRNX, check out Quiver Quantitative's $CRNX forecast page.
$CRNX Price Targets
Multiple analysts have issued price targets for $CRNX recently. We have seen 8 analysts offer price targets for $CRNX in the last 6 months, with a median target of $83.5.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $96.0 on 03/02/2026
- Richard Law from Goldman Sachs set a target price of $67.0 on 01/12/2026
- Jeffrey Hung from Morgan Stanley set a target price of $80.0 on 01/06/2026
- Leland Gershell from Oppenheimer set a target price of $87.0 on 09/30/2025
- Joseph Schwartz from Leerink Partners set a target price of $88.0 on 09/29/2025
- Jonathan Wolleben from JMP Securities set a target price of $143.0 on 09/26/2025
- Brian Skorney from Baird set a target price of $62.0 on 09/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
